CENTEK(SZ:000931) Jin Rong Jie·2026-02-05 10:49Core Viewpoint - The announcement indicates that Duoduo Pharmaceutical Co., Ltd. has received a notice of acceptance from the National Medical Products Administration for the consistency evaluation application of Sodium Cytidine Injection, marking a significant step in the drug's regulatory process [1] Group 1: Product Information - The drug in question is Sodium Cytidine Injection, with a specification of 2ml:0.25g (calculated as C14H26N4O11P2) [1] - The application pertains to the consistency evaluation for domestically produced drugs, which is crucial for ensuring quality and efficacy [1] Group 2: Historical Context - Sodium Cytidine Injection was approved for market release in 1987, with the approval number Guo Yao Zhun Zi H19993355 [1] - The drug is indicated for conditions such as cerebral blood supply disorders due to thrombosis or vascular rupture, particularly during acute and subacute phases, as well as for traumatic brain injuries [1] Group 3: Financial Investment - As of the date of the announcement, the project has accumulated research and development expenses totaling 2.4575 million yuan [1]